Inotiv, Inc. (NASDAQ:NOTV) CFO Beth Taylor Sells 4,370 Shares

Inotiv, Inc. (NASDAQ:NOTV) CFO Beth Taylor sold 4,370 shares of Inotiv stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $4.01, for a total value of $17,523.70. Following the transaction, the chief financial officer now owns 108,368 shares of the company’s stock, valued at $434,555.68. The trade was a 3.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Beth Taylor also recently made the following trade(s):

• On Friday, January 31st, Beth Taylor sold 2,054 shares of Inotiv stock. The stock was sold at an average price of $4.46, for a total value of $9,160.84.

Inotiv Stock Up 9.0 %

Shares of NOTV stock traded up $0.35 during mid-day trading on Thursday, hitting $4.25. The company’s stock had a trading volume of 882,402 shares, compared to its average volume of 695,682. Inotiv, Inc. has a 52-week low of $1.23 and a 52-week high of $11.42. The business has a 50-day moving average price of $4.37 and a 200 day moving average price of $2.93. The company has a debt-to-equity ratio of 2.31, a quick ratio of 1.28 and a current ratio of 1.57. The stock has a market cap of $143.31 million, a price-to-earnings ratio of -0.92 and a beta of 3.58.

Inotiv (NASDAQ:NOTV) last posted its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.41% and a negative net margin of 25.40%. Research analysts predict that Inotiv, Inc. will post -0.79 EPS for the current fiscal year.

Institutional Trading of Inotiv

Several hedge funds have recently bought and sold shares of NOTV. Balyasny Asset Management L.P. grew its holdings in Inotiv by 7,714.8% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,303,741 shares of the company’s stock valued at $5,397,000 after purchasing an additional 1,287,058 shares during the period. Kennedy Capital Management LLC bought a new position in shares of Inotiv during the fourth quarter valued at approximately $5,250,000. Vantage Point Financial LLC bought a new position in shares of Inotiv during the fourth quarter valued at approximately $1,393,000. Millennium Management LLC grew its stake in shares of Inotiv by 553.7% during the fourth quarter. Millennium Management LLC now owns 287,899 shares of the company’s stock valued at $1,192,000 after buying an additional 243,860 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Inotiv during the fourth quarter valued at approximately $737,000. Institutional investors own 18.17% of the company’s stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.